The association between plasma homocysteine and coronary heart disease is modified by the MTHFR 677C>T polymorphism

Heart

Volumn 99, Issue 23, 2013, Pages 1761-1765

  Mehlig, K ^a   Leander, K ^b   De Faire, U ^b   Nyberg, F ^a,c   Berg, C ^d   Rosengren, A ^d   Bjorck L ^d   Zetterberg, H ^d,e   Blennow, K ^d   Tognon, G ^a   Toren K ^a   Strandhagen, E ^a   Lissner, L ^a   Thelle, D ^a,f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; OBESITY; PHYSICAL ACTIVITY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; UNSTABLE ANGINA PECTORIS;

MYOCARDIAL ISCHAEMIA AND INFARCTION (IHD);

AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84888031844     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304460     Document Type: Article

References (30)

1. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
2. Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annual Rev Med 1998;49:31-62.
3. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202.
4. Varga EA, Sturm AC, Misita CP, et al. Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation 2005;111:e289-93.
5. Ebbing M, Bonaa KH, Arnesen E, et al. Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. J Intern Med 2010;268:367-82.
6. Haynes R, Clarke R. Homocysteine, the kidney, and vascular disease. BMJ 2012;344:e3925.
7. Wald DS, Morris JK, Wald NJ. Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. PloS one 2011;6:e16473.
8. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72:315-23.
9. Christen WG, Ajani UA, Glynn RJ, et al. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000; 160:422-34.
10. Ueland PM, Refsum H, Beresford SA, et al. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
11. Zylberstein DE, Bengtsson C, Bjorkelund C, et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 2004;109:601-6.
12. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10:111-13.
13. Sharma P, Senthilkumar RD, Brahmachari V, et al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis 2006;5:1.
14. Girelli D, Friso S, Trabetti E, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998;91:4158-63.
15. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-31.
16. Huh HJ, Chi HS, Shim EH, et al. Gene - nutrition interactions in coronary artery disease: correlation between the MTHFR C677T polymorphism and folate and homocysteine status in a Korean population. Thromb Res 2006;117:501-6.
17. Clarke R, Bennett DA, Parish S, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 2012;9:e1001177.
18. Yang Q, Bailey L, Clarke R, et al. Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000 US adults. Am J Clin Nutr 2012;95:1245-53.
19. Kadziela J, Janas J, Dzielinska Z, et al. The C677T mutation in methylenetetrahydrofolate reductase gene, plasma homocysteine concentration and the risk of coronary artery disease. Kardiol Pol 2003;59:17-26; discussion.
20. Lin PT, Huang MC, Lee BJ, et al. High plasma homocysteine is associated with the risk of coronary artery disease independent of methylenetetrahydrofolate reductase 677C→T genotypes. Asia Pac J Clin Nutr 2008;17:330-8.
21. Reuterwall C, Hallqvist J, Ahlbom A, et al. Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group. J Intern Med 1999;246:161-74.
22. Magera MJ, Lace y JM, Casetta B, et al. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem 1999;45:1517-22.
23. Zetterberg H, Regland B, Palmer M, et al. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet 2002;10:113-18.
24. Olsson B, Gigante B, Mehlig K, et al. Apolipoprotein C-I genotype and serum levels of triglycerides, C-reactive protein and coronary heart disease. Metabolism 2010;59:1736-41.
25. Gustavsson J, Mehlig K, Leander K, et al. Interaction of apolipoprotein E genotype with smoking and physical inactivity on coronary heart disease risk in men and women. Atherosclerosis 2012;220:486-92.
26. Strandhagen E, Berg C, Lissner L, et al. Selection bias in a population survey with registry linkage: potential effect on socioeconomic gradient in cardiovascular risk. Eur J Epidemiol 2010;25:163-72.
27. Harris RJ, Bradburn MJ, Deeks JJ, et al. metan: fixed- and random-effects meta-analysis. Stata J 2008;8:3-28.
28. Hwang SJ, Beaty TH, Liang KY, et al. Minimum sample size estimation to detect gene-environment interaction in case-control designs. Am J Epidemiol 1994;140:1029-37.
29. Ducros V, Demuth K, Sauvant MP, et al. Methods for homocysteine analysis and biological relevance of the results. J Chromatogr B Analyt Technol Biomed Life Sci 2002;781:207-26.
30. Strandhagen E, Zetterberg H, Aires N, et al. The methylenetetrahydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: a randomized placebo controlled study. Int J Mol Med 2004;13:811-15.